Advertisement
News
Advertisement

Pivotal Therapeutics Files Five International Patent Applications

Wed, 02/22/2012 - 6:45am
The Associated Press

(http://www.pivotaltherapeutics.us/)

Pivotal Therapeutics Inc. (CNSX:PVO), a specialty pharmaceutical

company with a focus on the treatment of cardiovascular disease and

overall health, announced today that it has filed five international

patent applications under the Patent Cooperation Treaty (PCT),

directed toward its novel lead product VASCAZEN, and combinations

thereof with certain cardiovascular treatment agents. The PCT is an

international patent application. A PCT application has the effect of

a national application for a patent in any of the 142 designated PCT

countries, and thereby secures patent pending status for VASCAZEN in

all the designated countries. This filing follows from the Provisional

Patent filings of last year, adding significant data demonstrating the

unique properties of VASCAZEN.

"The filing of these PCT patent applications is a critical step in

Pivotal's strategy for securing global Intellectual Property rights

for VASCAZEN" says Rachelle MacSweeney, President of Pivotal

Therapeutics. "These filings represent the culmination of research

conducted over the last several years which quantify the unique

properties of our product's ultra high purity prescription-grade

Omega-3 formulation in meeting the dietary Omega-3 deficient needs of

patients with cardiovascular disease, by elevating Eicosapentaenoic

(EPA) and Docosahexaenoic (DHA) to levels associated with a reduced

risk of cardiovascular complications".

By ensuring that VASCAZEN's unique EPA to DHA ratio fish oils are of

the highest purity, Pivotal Therapeutics is able to maximize the

correction of the dietary deficiency provided by VASCAZEN either

alone or in combination with other active ingredients in

cardiovascular patients.

"Pivotal's latest patent filings create value while demonstrating its

dedication to producing novel prescription medical food products that

further the goal of continuing to develop cutting edge medical foods

for the dietary management of patients with a variety of metabolic

deficiencies," says Dr. George Jackowski, Chief Scientific Officer &

Chair of Pivotal Therapeutics.

About Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal

Therapeutics is a publicly traded (CNSX:PVO) specialty pharmaceutical

company with a focus on the treatment of cardiovascular disease and

overall health. Pivotal Therapeutics' lead product VASCAZEN is a

prescription only medical food formulated to meet the dietary Omega-3

deficient needs of patients with cardiovascular disease through

elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels

associated with reduced risk of cardiovascular complications.

OMAZEN is a greater than 90% pure, proprietary EPA:DHA fatty acid

formulation commercialized for sale and distribution in Canada for the

maintenance of good health through elevating Omega-3 fatty acid

levels. The unique formulation and dosage will be available to

patients and consumers who realize the health benefits of Omega-3

supplementation with a quality product.

VASCAZEN is a greater than 90% pure, proprietary EPA:DHA fatty acid

formulation, protected by a series of both issued and pending US and

foreign patents and commercialized by prescription only. This unique

formulation will provide the cornerstone upon which a family of

cutting edge combination products, with efficacy across a broad

spectrum of cardiac care, will be commercialized.

Disclosure Notice

The information contained in this document is as of February 22, 2012.

This press release contains forward-looking statements. Such

forward-looking statements are subject to a number of risks,

assumptions and uncertainties that could cause Pivotal's actual

results to differ materially from those projected in such

forward-looking statements. These statements can be identified by the

use of words such as "will", "anticipate", "estimate", "expect",

"project", "forecast", "intend", "plan", "believe", "project",

"potential", and similar expressions with any discussion of future

operating or financial performance or events. In particular, factors

that could cause actual results to differ materially from those in

forward looking statements include the following: Pivotal's inability

to obtain additional financing on acceptable terms; growth in costs

and expenses; inability to compete with others who provide comparable

products; risk that the Company's products will not gain widespread

market acceptance; risks relating to the Company's ability to maintain

its CSNX listing. Forward-looking statements speak only as of the date

made and are not guarantees of future performance. The Company

undertakes no obligation to publicly update or revise any

forward-looking statements contained in this document as a result of

new information or future events or developments.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading